Last updated: August 6, 2026
OFORTA, the oral fludarabine phosphate product for previously treated B-cell chronic lymphocytic leukemia, is a discontinued U.S. oncology product with no meaningful current branded revenue base. Its commercial decline resulted from a narrow treatment population, competition from intravenous fludarabine and combination chemotherapy, later displacement by targeted CLL therapies, and limited remaining exclusivity. Sanofi does not report OFORTA as a separate revenue line, so product-level sales, profitability, and cumulative revenue cannot be established from public filings.
What was OFORTA and how was it used?
OFORTA was an oral tablet formulation of fludarabine phosphate, a purine nucleoside analog. The product was approved in the United States under NDA 21-552 for adults with B-cell chronic lymphocytic leukemia whose disease had not responded to, or had progressed during or after, at least one standard alkylating-agent-containing regimen.[1]
The labeled dose was 40 mg/m² orally once daily for five consecutive days in a 28-day cycle. The tablets were supplied as 10 mg strengths, requiring dose calculation and multiple tablets per treatment course.[1]
| Product attribute |
OFORTA |
| Active ingredient |
Fludarabine phosphate |
| Dosage form |
Oral tablet |
| Strength |
10 mg |
| Therapeutic area |
B-cell chronic lymphocytic leukemia |
| FDA application |
NDA 21-552 |
| U.S. approval |
2001 |
| Original commercial context |
Previously treated CLL |
| Product status |
Discontinued in the U.S. |
| Biologic status |
Not a biologic |
| Biosimilar pathway |
Not applicable |
Fludarabine suppresses DNA synthesis and has clinically important immunosuppressive and myelosuppressive effects. The product’s safety profile included severe cytopenias, infections, autoimmune hemolytic anemia, neurotoxicity, and immunosuppression.[1]
When did OFORTA lose exclusivity and commercial relevance?
OFORTA lost commercial relevance before the CLL market fully transitioned to targeted therapies. The original regulatory exclusivity and any meaningful patent protection associated with the product have long expired. The product is no longer positioned as a current branded growth asset.
The commercial timeline is best understood as follows:
| Period |
Market event |
Commercial impact |
| 2001 |
FDA approval of OFORTA tablets |
Created an oral option for previously treated B-cell CLL |
| Early 2000s |
Fludarabine-based chemotherapy remained an established CLL treatment class |
Supported a limited oncology market |
| Late 2000s to early 2010s |
Increasing safety concerns around purine analogs and combination chemotherapy |
Reduced the appeal of oral fludarabine |
| 2010s |
Chemoimmunotherapy and then targeted agents changed CLL treatment sequencing |
Contracted the addressable market |
| Subsequent years |
OFORTA discontinued in the U.S. |
Eliminated the branded U.S. revenue opportunity |
FDA records and drug reference databases identify OFORTA as discontinued rather than as an actively marketed product.[2][3] The discontinuation was not the same as a new-product launch failure in a growth market. It occurred in a therapeutic category that was becoming less attractive because clinicians had more effective and better-positioned alternatives.
What is the FDA regulatory status of OFORTA?
OFORTA is a conventional small-molecule prescription drug, not a biologic. The relevant regulatory pathway was a new drug application, not a biologics license application. Biosimilar risk therefore does not apply.
The practical regulatory status is:
- The original U.S. NDA exists as a legacy approval record.
- The branded tablet product is no longer commercially available in the U.S.
- The product does not have a current commercial exclusivity period.
- Any future fludarabine tablet entrant would face an abbreviated pathway or other conventional generic-drug pathway, subject to FDA requirements.
- The presence of an old NDA does not create a current branded market.
The injectable fludarabine market is separate from the OFORTA tablet market. A generic injectable product can compete with branded or legacy injectable fludarabine without establishing commercial availability of oral OFORTA.
What patents protected OFORTA?
OFORTA does not have a commercially meaningful remaining U.S. patent estate. Fludarabine phosphate is an established active ingredient, and the primary product opportunity is outside the normal life cycle for branded composition-of-matter protection.
The relevant protection categories are:
| Protection category |
OFORTA position |
| Active-ingredient patent |
Expired or commercially irrelevant |
| Tablet formulation patent |
No known active protection supporting a current branded market |
| Method-of-use patent |
No current exclusivity of practical commercial significance |
| Pediatric exclusivity |
No current effect on market access |
| Orphan-drug exclusivity |
No current U.S. exclusivity supporting OFORTA |
| Orange Book listing |
No active listing that supports a present branded franchise |
| Manufacturing know-how |
Potentially relevant operationally, but not a material market barrier |
The product’s patent risk is therefore asymmetric. A generic manufacturer would face low intellectual-property risk but high commercial execution risk. The main obstacles would be demonstrating demand, sourcing validated fludarabine phosphate, managing cytotoxic manufacturing requirements, and obtaining sufficient hospital and specialty-pharmacy utilization.
Are there Paragraph IV challenges to OFORTA?
No current Paragraph IV dispute appears to have commercial significance for OFORTA. A Paragraph IV certification is relevant when a generic applicant challenges an unexpired Orange Book-listed patent. OFORTA’s branded product has already left the U.S. commercial market, and there is no evident active patent barrier sustaining a live branded franchise.
The absence of a prominent Paragraph IV case does not imply that the product was unchallenged during its commercial life. It indicates that current generic litigation is not the primary market issue. Any future generic sponsor would likely evaluate the market as a low-volume, legacy oncology opportunity rather than as a high-value patent challenge.
What formulations are protected by OFORTA?
The commercial formulation was an oral 10 mg tablet. The formulation delivered fludarabine phosphate systemically but did not create a durable platform franchise comparable with extended-release, depot, inhaled, transdermal, or device-based products.
No major formulation barrier is associated with OFORTA. The product’s technical profile is relatively conventional:
- Immediate-release oral tablet.
- Established small-molecule active ingredient.
- No device dependency.
- No biologic stability requirement.
- No specialized administration system.
- No known formulation protection that remains commercially decisive.
Manufacturing still requires controls appropriate for a cytotoxic oncology compound. Those controls can raise operating costs and quality-system requirements, but they are not equivalent to a patent barrier.
How strong is the OFORTA patent estate?
The OFORTA patent estate is weak from a current commercial perspective.
Patent strength should be assessed across four dimensions:
| Dimension |
Assessment |
| Remaining term |
Minimal to none |
| Claim breadth |
Limited practical value for a legacy oral fludarabine product |
| Regulatory exclusivity |
Expired |
| Ability to support premium pricing |
None in the current U.S. market |
The strongest historical protection would have been associated with the original regulatory approval and any product-specific filings. Those protections cannot support current premium pricing. A new entrant would be more likely to compete on availability and procurement economics than on patent differentiation.
Which companies challenged or displaced OFORTA?
The direct competitive set included fludarabine injection products, generic chemotherapy suppliers, and CLL regimens containing fludarabine. The more important displacement came from drugs that changed standard treatment rather than from a single generic tablet challenger.
Direct and historical competitors
- Fludara and other fludarabine injection products.
- Generic fludarabine phosphate injection.
- Chlorambucil-based regimens.
- FCR combinations involving fludarabine, cyclophosphamide, and rituximab.
- Bendamustine-based regimens.
Later therapeutic competitors
- Ibrutinib.
- Acalabrutinib.
- Zanubrutinib.
- Venetoclax.
- Obinutuzumab-containing regimens.
- Other targeted or combination therapies used in treatment-naive and relapsed CLL.
The shift toward Bruton tyrosine kinase inhibitors and BCL-2 inhibition reduced the role of purine analogs. Fludarabine-based regimens became less attractive because of cumulative marrow toxicity, infection risk, immune suppression, and the availability of targeted treatment options.[4][5]
What is the revenue exposure for OFORTA?
Sanofi’s public financial reporting does not disclose OFORTA revenue separately. The product’s contribution would have been embedded within broader pharmaceutical or oncology reporting, making product-level revenue reconstruction unreliable.[6]
The financial trajectory can be classified into four phases:
Launch and niche adoption
OFORTA entered a market with an established clinical need for relapsed or refractory CLL. Oral dosing offered convenience relative to intravenous administration. The opportunity was constrained by the small eligible population and the need for close hematologic monitoring.
Limited growth
The product did not have the profile of a broad primary-care or specialty blockbuster. CLL was a relatively small hematologic malignancy market, and OFORTA was directed at a later-line population. Reimbursement, toxicity management, and physician familiarity with injectable fludarabine limited the upside.
Decline
The product faced declining demand as treatment patterns moved toward chemoimmunotherapy and then targeted agents. The risk-benefit profile of purine analog therapy became less competitive, particularly for patients with comorbidities, prior treatment exposure, or high infection risk.
Post-discontinuation
Current OFORTA revenue is effectively zero in the U.S. branded market because the product is discontinued. Any residual economic activity would relate to legacy references, regulatory records, or alternative fludarabine products rather than active OFORTA sales.
What generic entry risks exist for OFORTA?
Generic entry risk is low in the traditional patent-litigation sense and high in the demand-validation sense.
A new generic oral fludarabine product could face:
- Limited patient volume.
- Reduced physician demand.
- Competition from injectable alternatives.
- Competition from modern targeted CLL therapies.
- Cytotoxic manufacturing and handling requirements.
- Potentially weak reimbursement economics.
- Difficulty obtaining a sustainable commercial margin.
- Limited pharmacy stocking incentives.
The most plausible launch scenario would be a small specialty supplier serving hospitals, oncology practices, or patients with a specific clinical need for oral administration. A large generic launch with substantial promotional investment is unlikely to be economically attractive.
How does OFORTA compare with injectable fludarabine?
| Factor |
OFORTA tablets |
Fludarabine injection |
| Administration |
Oral |
Intravenous |
| Main advantage |
Avoids infusion administration |
Established clinical use and dosing familiarity |
| Main limitation |
Discontinued U.S. availability and narrow demand |
Infusion burden and cytotoxic handling |
| Patent position |
No meaningful current protection |
Genericized market |
| Commercial status |
Legacy/discontinued branded product |
Alternative products may remain available |
| Current treatment relevance |
Low |
Also reduced by targeted CLL agents |
| Reimbursement outlook |
Limited standalone opportunity |
Institutional and oncology procurement channels |
OFORTA’s oral route was commercially differentiated, but route convenience alone was insufficient to sustain the product after the treatment paradigm changed.
What licensing deals affected OFORTA?
No major current licensing transaction is publicly associated with OFORTA. The product was commercialized within a larger pharmaceutical portfolio, and public corporate disclosures do not identify a separate OFORTA licensing stream, royalty burden, or asset sale of material current value.
Any historical rights arrangements would have limited relevance to present valuation because the U.S. product is discontinued and its exclusivity has expired.
What patent litigation affects OFORTA?
No active U.S. patent litigation involving OFORTA appears to affect current market access, launch timing, or valuation. The relevant legal conclusion is that litigation is not the principal commercial variable. Product availability, clinical obsolescence, and market size are more important.
What is the outlook for OFORTA?
The U.S. outlook is inactive. OFORTA has no credible branded growth trajectory, no meaningful remaining exclusivity, and no identifiable current revenue base. A revival would require a new commercial strategy, renewed regulatory activity, and evidence that an oral fludarabine niche remains clinically and economically relevant.
A future oral fludarabine entrant could find limited demand in selected settings, but the market would be defensive and procurement-driven. The strongest commercial case would involve supply restoration for a defined patient population, not a broad CLL franchise.
Key Takeaways
- OFORTA is the discontinued oral fludarabine phosphate tablet product for previously treated B-cell CLL.
- The product received FDA approval in 2001 under NDA 21-552.
- U.S. branded OFORTA revenue is no longer a live commercial stream.
- Sanofi does not publicly report OFORTA-specific revenue or profit.
- No active patent or regulatory exclusivity appears to support a current branded market.
- Paragraph IV litigation is not a current commercial issue.
- Generic entry would be technically feasible but commercially unattractive because demand is narrow and CLL treatment has shifted to targeted agents.
- The principal competitive threat came from therapeutic displacement, not from a single patent challenger.
- OFORTA has no biosimilar risk because it is a conventional small-molecule drug.
- Any future oral fludarabine opportunity would be a low-volume specialty market.
FAQs
Is OFORTA still available in the United States?
No. OFORTA is identified as a discontinued U.S. product. Other fludarabine formulations may be available through separate products and suppliers.
What company manufactured OFORTA?
OFORTA was associated with Sanofi and its U.S. pharmaceutical operations. The product was commercialized within the company’s oncology portfolio rather than as a separately reported public company segment.
Is fludarabine still used to treat CLL?
Fludarabine remains a recognized oncology drug, but its role in CLL has contracted substantially. Targeted therapies and newer combination regimens have displaced much historical purine analog use.
Could a generic company relaunch oral fludarabine?
A relaunch is technically possible, but the commercial case is weak. The principal risks are low patient volume, limited physician demand, competing treatments, and cytotoxic manufacturing requirements.
Does OFORTA have orphan-drug protection?
No current orphan-drug exclusivity appears to support OFORTA’s U.S. market position. Any historical exclusivity would have expired and would not restore the discontinued branded franchise.
References
-
U.S. Food and Drug Administration. (2001). OFORTA (fludarabine phosphate) tablets, prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: OFORTA, NDA 021552. FDA.
-
National Library of Medicine. (n.d.). Oforta: Fludarabine phosphate tablet drug information. DailyMed.
-
National Comprehensive Cancer Network. (2024). NCCN clinical practice guidelines in oncology: Chronic lymphocytic leukemia/small lymphocytic lymphoma. NCCN.
-
Hallek, M., Al-Sawaf, O., & others. (2023). Treatment developments in chronic lymphocytic leukemia and the changing role of chemoimmunotherapy. Blood.
-
Sanofi. (2001-2012). Annual reports and regulatory filings. Sanofi.
